# Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy

> **NCT02559830** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shenzhen Second People's Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Metachromatic Leukodystrophy
- Adrenoleukodystrophy

## Interventions

- **GENETIC:** transduced CD34+ hematopoietic stem cell

## Key facts

- **NCT ID:** NCT02559830
- **Lead sponsor:** Shenzhen Second People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01
- **Primary completion:** 2025-10
- **Final completion:** 2025-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-05-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02559830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02559830, "Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02559830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*